|
[1]
|
COVID-19 Dashboard. Center for systems science and engineering at Johns Hopkins University. 2022. https://coronavirus.jhu.edu/map.html. [2022-6-5].https://coronavirus.jhu.edu/map.html |
|
[2]
|
Covino M, Russo A, Salini S, De Matteis G, Simeoni B, Della Polla D, et al. Frailty assessment in the emergency department for risk stratification of COVID-19 patients aged ≥80 years. J Am Med Dir Assoc 2021;22(9):1845 − 52.e1. http://dx.doi.org/10.1016/j.jamda.2021.07.005CrossRef
|
|
[3]
|
Liu SJ, Xu EP, Liu Y, Xu YY, Wang J, Du J, et al. Factors associated with pneumococcal vaccination among an urban elderly population in China. Hum Vacc Immunother 2014;10(10):2994 − 9. http://dx.doi.org/10.4161/21645515.2014.972155CrossRef
|
|
[4]
|
Wagner AL, Montgomery JP, Xu WT, Boulton ML. Influenza vaccination of adults with and without high-risk health conditions in China. J Public Health 2017;39(2):358 − 65. http://dx.doi.org/10.1093/pubmed/fdw041CrossRef
|
|
[5]
|
National Health Commission. Transcript of regular press conference on Apr 8, 2021. 2021. http://www.nhc.gov.cn/xcs/s3574/202104/0c1cf92f2b7b4cfe890234a1c3d5593f.shtml. [2022-6-26]. (In Chinese). http://www.nhc.gov.cn/xcs/s3574/202104/0c1cf92f2b7b4cfe890234a1c3d5593f.shtml |
|
[6]
|
Kidd M, De Toca L. Editorial: the contribution of Australia’s general practitioners to the COVID-19 vaccine rollout. Aust J Gen Pract 2021;50(12):871 − 2. http://dx.doi.org/10.31128/AJGP-11-21-6235CrossRef
|
|
[7]
|
Meng ZG, Shan SJ, Zhang RL. China's COVID-19 vaccination strategy and its impact on the global pandemic. Risk Manag Healthc Policy 2021;14:4649 − 55. http://dx.doi.org/10.2147/RMHP.S338701CrossRef
|
|
[8]
|
Wagner AL, Porth JM, Wu ZK, Boulton ML, Finlay JM, Kobayashi LC. Vaccine hesitancy during the COVID-19 pandemic: a latent class analysis of middle-aged and older US adults. J Community Health 2022;47(3):408 − 15. http://dx.doi.org/10.1007/s10900-022-01064-wCrossRef
|
|
[9]
|
Gatwood J, McKnight M, Fiscus M, Hohmeier KC, Chisholm-Burns M. Factors influencing likelihood of COVID-19 vaccination: a survey of Tennessee adults. Am J Health Syst Pharm 2021;78:879 − 89. http://dx.doi.org/10.1093/ajhp/zxab099CrossRef
|
|
[10]
|
McMenamin ME, Nealon J, Lin Y, Wong JY, Cheung JK, Lau EHY, et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. Lancet Infect Dis 2022. http://dx.doi.org/10.1016/S1473-3099(22)00345-0.http://dx.doi.org/10.1016/S1473-3099(22)00345-0 |
|
[11]
|
China Government Website. Transcript of press conference of the joint prevention and control mechanism of the state council on Mar 25, 2022. 2022. http://www.gov.cn/xinwen/gwylflkjz189/index.htm. [2022-9-1]. (In Chinese). http://www.gov.cn/xinwen/gwylflkjz189/index.htm |
|
[12]
|
Wang ZX, Fang Y, Yu FY, Chan PSF, Chen SY, Sun FH. Facilitators and barriers to take up a COVID-19 vaccine booster dose among community-dwelling older adults in Hong Kong: a population-based random telephone survey. Vaccines 2022;10(6):966. http://dx.doi.org/10.3390/VACCINES10060966CrossRef
|
|
[13]
|
National Health Commission. Knowledge about monitoring suspected adverse reactions following vaccination. 2016. http://www.nhc.gov.cn/xcs/s3574/201604/9ee6152c8e6e45a38737f1bf4120e504.shtml. [2022-7-19]. (In Chinese). http://www.nhc.gov.cn/xcs/s3574/201604/9ee6152c8e6e45a38737f1bf4120e504.shtml |
|
[14]
|
Centers for Disease Control and Prevention. Vaccine adverse event reporting system (VAERS). 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vaers.html. [2022-7-16].https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vaers.html |
|
[15]
|
Centers for Disease Control and Prevention. V-safe after vaccination health checker. 2022. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafe.html. [2022-7-19].https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafe.html |
|
[16]
|
Mazur A, Benitez S, Chuffart-Finsterwald S, La Rotta R, Hampton LM. COVAX no fault compensation program for COVID-19 vaccine injuries in 92 low and middle income countries. Vaccine 2021;39(49):7128 − 30. http://dx.doi.org/10.1016/j.vaccine.2021.10.047CrossRef
|
|
[17]
|
Tangcharoensathien V, Sachdev S, Viriyathorn S, Sriprasert K, Kongkam L, Srichomphu K, et al. Universal access to comprehensive COVID-19 services for everyone in Thailand. BMJ Glob Health 2022;7:e009281. http://dx.doi.org/10.1136/bmjgh-2022-009281CrossRef
|